SOPHiA GENETICS Reports Financial Results for the Second Quarter of Fiscal 2023

Aug 8 2023
Robust growth and efficient expense execution continues BOSTON and ROLLE, Switzerland, Aug. 08, 2023 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today reported financial results for the second quarter ended June 30,

Read more

Build something bigger than your career

Enjoyed learning about life at SOPHiA from our blogs? Here are a few of our open roles

Title Country Department
IVDR Expert (Regulatory Affairs) Switzerland. United Kingdom. United States Regulatory & Quality
Subject Matter Expert - APAC Malaysia. Singapore Clinical Sales
Senior Director, Clinical & BioPharma Operations Switzerland Medical
Sr Manager, Genomic Implementation Solutions United States Clinical Sales
Deal Desk and Commercial Operations Manager Switzerland. United States Clinical Sales